Pablo Tebas, MD
University of Pennsylvania
14
13
12
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+13 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (14)
Showing 10 of 14 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
David Stein, MD
Jacobi Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Luis Montaner, DVM, PhD
The Wistar Institute
Shared therapeutic areas:
Worked with same sponsors:
Jeffrey Jacobson, MD
Drexel University College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Karam Mounzer, MD
Jonathan Lax Immune Disorders Clinic- Philadelphia FIGHT
Shared therapeutic areas:
Worked with same sponsors:
Jay Kostman, MD
Penn-Presbyterian Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Paolo Bonato, PhD
Spaulding Rehabilitation Hospital
Shared therapeutic areas:
Herbert B Slade, MD
Healthpoint
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
James C Eisenach, MD
Wake Forest University Health Sciences
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (14)
Showing 14 of 14 trials
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection
Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
All 14 trials loaded